These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 31511184)
21. Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: a simulation study. Zafari Z; Lynd LD; FitzGerald JM; Sadatsafavi M J Allergy Clin Immunol; 2014 Oct; 134(4):908-915.e3. PubMed ID: 24875619 [TBL] [Abstract][Full Text] [Related]
22. Economic Evaluations of Multicomponent Disease Management Programs with Markov Models: A Systematic Review. Kirsch F Value Health; 2016 Dec; 19(8):1039-1054. PubMed ID: 27987631 [TBL] [Abstract][Full Text] [Related]
23. Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations. Elliott J; van Katwyk S; McCoy B; Clifford T; Potter BK; Skidmore B; Wells GA; Coyle D Pharmacoeconomics; 2019 Oct; 37(10):1261-1276. PubMed ID: 31201643 [TBL] [Abstract][Full Text] [Related]
24. The Use of Decision-Analytic Models in Atopic Eczema: A Systematic Review and Critical Appraisal. McManus E; Sach T; Levell N Pharmacoeconomics; 2018 Jan; 36(1):51-66. PubMed ID: 28864846 [TBL] [Abstract][Full Text] [Related]
25. Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter? Dilokthornsakul P; Chaiyakunapruk N; Campbell JD J Asthma; 2017 Jan; 54(1):17-23. PubMed ID: 27284904 [TBL] [Abstract][Full Text] [Related]
26. The Cost-Effectiveness of Digital Health Interventions on the Management of Cardiovascular Diseases: Systematic Review. Jiang X; Ming WK; You JH J Med Internet Res; 2019 Jun; 21(6):e13166. PubMed ID: 31210136 [TBL] [Abstract][Full Text] [Related]
27. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years. Walker S; Burch J; McKenna C; Wright K; Griffin S; Woolacott N Health Technol Assess; 2011 May; 15 Suppl 1():13-21. PubMed ID: 21609649 [TBL] [Abstract][Full Text] [Related]
28. Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath. Harnan SE; Tappenden P; Essat M; Gomersall T; Minton J; Wong R; Pavord I; Everard M; Lawson R Health Technol Assess; 2015 Oct; 19(82):1-330. PubMed ID: 26484874 [TBL] [Abstract][Full Text] [Related]
29. Empowering pharmacists in asthma management through interactive SMS (EmPhAsIS): study protocol for a randomized controlled trial. De Vera MA; Sadatsafavi M; Tsao NW; Lynd LD; Lester R; Gastonguay L; Galo J; FitzGerald JM; Brasher P; Marra CA Trials; 2014 Dec; 15():488. PubMed ID: 25494702 [TBL] [Abstract][Full Text] [Related]
30. Generating evidence to inform health technology assessment of treatments for SLE: a systematic review of decision-analytic model-based economic evaluations. Gavan S; Bruce I; Payne K Lupus Sci Med; 2020 Jul; 7(1):. PubMed ID: 32723809 [TBL] [Abstract][Full Text] [Related]
31. Systematic review of models used in economic analyses in moderate-to-severe asthma and COPD. Einarson TR; Bereza BG; Nielsen TA; Van Laer J; Hemels ME J Med Econ; 2016; 19(4):319-55. PubMed ID: 26535917 [TBL] [Abstract][Full Text] [Related]
32. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada. Ismaila AS; Risebrough N; Li C; Corriveau D; Hawkins N; FitzGerald JM; Su Z Respir Med; 2014 Sep; 108(9):1292-302. PubMed ID: 25175480 [TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of intensive interventions compared to standard care in individuals with type 2 diabetes: A systematic review and critical appraisal of decision-analytic models. Usman M; Khunti K; Davies MJ; Gillies CL Diabetes Res Clin Pract; 2020 Mar; 161():108073. PubMed ID: 32061637 [TBL] [Abstract][Full Text] [Related]
34. Evaluating Cost-Effectiveness Models for Pharmacologic Interventions in Adults with Heart Failure: A Systematic Literature Review. Di Tanna GL; Bychenkova A; O'Neill F; Wirtz HS; Miller P; Ó Hartaigh B; Globe G Pharmacoeconomics; 2019 Mar; 37(3):359-389. PubMed ID: 30596210 [TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: A systematic review. Wong CKH; Liao Q; Guo VYW; Xin Y; Lam CLK Vaccine; 2017 May; 35(24):3153-3161. PubMed ID: 28476628 [TBL] [Abstract][Full Text] [Related]
36. Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer's Disease. Hernandez L; Ozen A; DosSantos R; Getsios D Pharmacoeconomics; 2016 Jul; 34(7):681-707. PubMed ID: 26899832 [TBL] [Abstract][Full Text] [Related]
37. Measuring costs and consequences in economic evaluation in asthma. Sculpher MJ; Price M Respir Med; 2003 May; 97(5):508-20. PubMed ID: 12735668 [TBL] [Abstract][Full Text] [Related]
38. Cost-utility analysis of once-daily versus twice-daily inhaled corticosteroid dosing for maintenance treatment of asthma in pediatric patients. Rodriguez-Martinez CE; Sossa-Briceño MP; Castro-Rodriguez JA J Asthma; 2016 Jun; 53(5):538-45. PubMed ID: 26786524 [TBL] [Abstract][Full Text] [Related]
39. Model-Based Economic Evaluations of Interventions for Dementia: An Updated Systematic Review and Quality Assessment. Darab MG; Engel L; Henzler D; Lauerer M; Nagel E; Brown V; Mihalopoulos C Appl Health Econ Health Policy; 2024 Jul; 22(4):503-525. PubMed ID: 38554246 [TBL] [Abstract][Full Text] [Related]
40. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]